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Abstract  
Sensitive detection of specific antibodies by biosensors has become of major importance for 
monitoring and controlling epidemics. Here we report a development of a biosensor able to specifically 
measure antibodies in a drop of unmodified blood serum. Within minutes, the detection system 
measures presence of antibodies against Plasmodium vivax, a causing agent for malaria. The biosensor 
consists of of a layer of carbon nanotubes (CNTs) which were casted on a carbon working electrode 
area of a three-electrode system and oxidized. An amine layer was produced next by modifying the 
surface with EDAC/NHS followed by reaction with a diamine compound. Finally, the protein 
fragments derived from P. vivax containing well-known antigen sequences were casted on this layer 
and bound through electrostatic interactions, involving hydrogen and ionic bonding. All these chemical 
changes occurring at the carbon surface along the biosensor assembly were followed and confirmed 
by Fourier Transformed Infrared s pectrometry (FTIR) and Raman spectroscopy.  
The presence of antibodies in serum was detected by monitoring the electrical properties of the layer, 
making use of cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS) and square 
wave voltammetry (SWV), against a standard iron probe. Overall, the charge-transfer resistance 
decreased after antibody binding, because there was an additional amount of protein bound to the 
surface.  This hindered the access of the iron redox probe to the conductive support at the electrode 
surface. Electrical changes could be measured at antibody concentration as low as ~6-50 pg/L 
(concentrations in the range of 10-15 M) and as high as ~70 g/L. Specific measurement with low 
background was even possible in undiluted serum. Hence, this novel biosensor allows assessing serum 
antibody levels in real time and in un-manipulated serum samples on-site where needed. 
 
Keywords: Biosensor; Immune response detection; Antibodies; Malaria; Electrochemical 
Measurements.  
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1. Introduction 
Infectious diseases are still emerging worldwide and remain a fundamental health-care and economical 
challenge (Fauci and Morens, 2012; Jones, et al., 2008, Morens, and Fauci, 2013). While diagnostic 
tests for a number of viral infectious diseases, such as HIV (Bateganya, at al., 2016; Chamie, et al., 
2016; Orkin, et al., 2016; Shahid, 2016) or hepatitis B (Bottero, et al., 2016; Orkin, et al., 2016) and C 
(Frimpong, et al,. 2016; Harris, et al., 2016; Orkin, et al., 2016) are well established and readily 
available, this is not the case for a large number of other infectious agents. Particularly prominent 
examples are several vector-borne diseases (such as Malaria, Zika, Chikungunya, Yellow Fever) as 
well as air-borne diseases (such as influenza), water-borne diseases (such as cholera, shigellosis, 
typhoid fever), epidemic meningitis and haemorrhagic fevers (such as Ebola virus disease, Marburg 
virus disease). It is the declared goal of leading health care institutions, such as the World Health 
Organization (WHO), to increase the global capacity to build capacity to mount a rapid, predictable 
and effective response to major epidemic and pandemic threats. This requires the implementation of 
programs that increase preparation, surveillance and effective responses to disease outbreaks  (Minikel, 
et al. 2016; WHO, 2014). Overall, these goals demand novel technologies, systems, and techniques 
that may increase the efficiency of disease recognition, diagnosis, intervention and control.  
Among the methods available for malaria diagnosis, the clinical diagnosis remains the dominant tool 
to recognize malaria, a rather ineffective method, however, as the clinical picture is often dominated 
by non-specific symptoms, such as fever and malaise (Genton, et al. 1994; Tjitra, et al. 1999; 
Nankabirwa, et al. 2009). Additional diagnostic tools include microscopic examination of blood 
samples or polymerase chain reaction (PCR) for parasite detection (Moody, 2002; Bailey, et al. 2013). 
Both involve rather sophisticated equipment often unavailable in endemic areas. Serological tests can 
also be used to detect antibodies against malaria parasites. This can be done either using indirect 
immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA) (Bailey, et al. 2013, 
Michael and Wilson, 2013). Overall, these assays work well in controlled clinical trials but require an 
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expensive laboratory structure for routine use in endemic areas. Novel, cost-effective and easy to 
implement and use methods are therefore required to improve diagnosis of malaria and other diseases 
in the field.  
One possible alternative towards the emerging need of point-of-care diagnosis, manage and control of 
epidemic diseases may be to create a simple device capable of monitoring the human immune response 
against the involved microorganisms (Chattopadhyay, et al., 2014; Fernández-Ruiz, et al. 2014, 
Furmana and Davis, 2015). The presence of an immune response and the levels of antibodies 
circulating in the body are often a crucial tool to help assessing a patient`s individual condition and 
disease history as well understanding the mechanics of the regional and global spread of the pathogen 
(Agarwal and Cunningham-Rundles, 2007; Li, et al., 2015; Sorci, et al., 2013). As far as we know, 
there is currently no technique readily available to perform such monitoring in real time under field 
conditions. In this context, the portability and simplicity of procedure is at the heart of the problem - a 
challenge that may be solved by cutting edge biosensing technologies (Caliendo, et al., 2013; D'Orazio, 
2011; Singh, et al., 2014; Zhang, et al. 2010). The current developments in nanotechnology have led 
to the generation of biosensors with many advantageous features when compared to conventional 
methods. These include low cost, portability, excellent sensitivity/selectivity features, simplicity of 
use and ability for detection in real time (Gao, et al., 2016; Godonoga, et al., 2016; Speicher and Pantel, 
2014, Wu, et al., 2016). 
There are few biosensors reported in the literature for tracking Malaria (reviewed recently by 
Rodovalho et al., 2015 and Brince-Paul et al., 2016. A brief description of their performance is given 
in table 1. Most methods aim at the detection of Plasmodium falciparum Histidine-rich protein 2 
(Sharma et al., 2008; Sharma et al., 2011; Brince-Paul et al., 2016). Other reports describe the detection 
of DNA fragments in malaria-infected blood (Ittarat et al., 2013) or measurement of Plasmodium 
lactate dehydrogenase activity (Lee at al., 2012). As far as we know, there is a single method devoted 
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to the determination of antibodies against Plasmodium falciparum in the blood (Sharma et al., 2010) 
and this method detected antibodies in rat serum down to a dilution of 1:102400. 
In the current study, we report a simple sensing layer that is capable of detecting and quantifying the 
human immune response against a given pathogen or parasite related to worldwide epidemic diseases. 
It is based on immobilization of specific antigenic regions to which antibodies circulating in the body 
after infection can bind with high specificity. The sensing layer is assembled on screen-printed 
electrodes to ensure portability and on-site analysis. This new principal is applied herein as proof-of-
concept to Malaria, one of the most prevalent infectious diseases having a yearly toll of more than 
438000 killed by the parasite (WHO, 2015). 
The new biosensor presented here enables point-of-care detection of antibodies against two important 
antigens of P. vivax infection, CSP (Circumsporozoite protein) and TRAP (Thrombospondin related 
anonymous protein) (Muller, 1993; Prudêncio, 2006; Sinnis and Sim, 1997). The biosensor was 
designed by placing a protein with the two epitope regions for the indicated antigens on a conductive 
nanotube surface. Antibodies against both antigens could be measured in a sensitive way and from 
undiluted serum, indicating that this novel type of biosensor may be readily used in field applications. 
Furthermore, it is probable that it may be used not only for the detection of anti-malaria antibodies but 
also for monitoring antibody responses against other emerging global threats such as Ebola- or Zika-
virus, provided that additional experiments are made to confirm such extended application and a 
portable apparatus can be designed.  
 
2. Experimental Section  
2.1 Procedures and materials involved in the protein production  
The chimeric CSP 210-247 was cloned in open reading frame of the central repeats from VK247 
(GenBank P08677) and VK210 (GenBank M69059.1) isoforms, between N and C terminal regions 
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from Salvador 1 strain of P. vivax (GenBank 5472322) into pHLsec mammalian expression vector and 
expressed by HEK 293T cells. PvTRAP was synthesised by Geneart™, followed by cloning  into 
pHLsec to produce protein. Essential details of this synthesis may be found in the supplementary 
section (S1 and S2). 
 
2.2 Apparatus 
The electrochemical measurements were performed with a Metrohm Autolab, PGSTAT320N, 
potentiostat/galvanostat, controlled by NOVA 1.11 software. The carbon-screen printed electrodes 
(Carbon-SPEs) were of commercial origin, produced by DropSens (DRP-C110) – any other carbon 
SPEs may also be applied herein. The three electrode system of the carbon-SPEs contained: i) a counter 
electrode made of carbon; ii) a reference electrode made of silver; and iii) a carbon working electrode 
of 4 mm diameter. All electrical connections were made in silver. The Carbon-SPEs were interfaced 
with the potentiostat by means of a switch box (also from DropSens). A representation/photograph of 
the equipment, SPE and resulting signals has been shown in Figure S1. 
 
2.3 Reagents  
All chemicals were of analytical grade and water was deionised (conductivity ˂ 0.1 µS/cm) or ultrapure 
Mili-Q laboratory grade. The chemical reagents including potassium hexacyanoferrate III 
(K3[Fe(CN)6]), potassium hexacyanoferrate II (K4[Fe(CN)6]) trihydrate, were obtained from Riedel-
deHäen; Ethylenediamine was obtained from Merck, N’-ethyl-N’-(3-Dimethylaminopropyl) 
carbodiimide hydrochloride (EDAC) was obtained from Alfa Aesar, N-Hydroxysuccinimide (NHS) 
was obtained from Fluka; N-Dimethylformamide (DMF) was obtained from Analar Normapur; 
Carboxylated CNTs were obtained from Sigma; and Phosphate Buffer Saline (PBS) was obtained from 
Amresco. 
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2.4 Electrochemical Procedures 
The electrochemical studies involved CV, EIS and SWV assays performed in the iron redox probe 
solution and under the following electrochemical conditions. CV assays were made by scanning 
potentials from -0.3 to +0.7 V, at 50 mV/s. EIS assays were established under a formal potential of 
+0.14V using a sinusoidal potential perturbation with amplitude 0.01V and 50 frequency values, 
logarithmically distributed from 0.1 to 100000 Hz; the data obtained was fitted to a Randles equivalent 
circuit using 1.11 Nova Software from Autolab. SWV assays were conducted from -0.3 to +0.7 V, 
with a frequency of 25Hz and the step height of to 50mV.  
Regarding specifically EIS data, Nyquist plots was used to plot the obtained spectra showing the 
frequency response of the electrolyte system and plotting the imaginary component (Z’’) of the 
impedance against its real component (Z’). EIS data was fitted into the typical Randle’s equivalent 
circuit, which matched the physiochemical processes occurring at the carbon electrode surface. This 
circuit was composed of several elements: resistance of the solution phase (Rs), capacitance of the 
double layer (Cdl), charge-transfer resistance (Rct) at the electrode surface and Warburg diffusion 
element (W). Rct was given by the diameter of the semicircle obtained in the plot. 
All electrochemical readings were made by casting a volume of about ~80 µL of the solution under 
analysis on the three-electrode system of the SPE. This volume was enough to cover all electrodes, 
which is a requirement of the electrochemical analysis. The CV, SWV and EIS measures were made 
immediately after.  
 
2.5 Synthesis of the sensing layer 
The overall changes made on the carbon electrode area are presented in Figure 1. In brief, a suspension 
of 1 mg of carboxylated CNTs in DMF was dispersed in ultrasounds for 1h. After that, a volume of 6 
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µL of this suspension was casted on the carbon electrode area and let dry at 70 ºC for 30 minutes. This 
procedure was repeated three times. The carboxylic groups on the surface were activated by casting 6 
µL of a solution containing EDAC (0.025M) and NHS (0.0125M) freshly prepared in PBS and mixed 
for 1h30, at room temperature. This solution was removed and replaced by 6 µL of a 0.02M 
ethylenediamine solution in PBS and cast for 60 minutes. The peptide with the antigen regions 
CSP210-247 was immobilized by casting 6 µL of a 2.8 µg/ml peptide CSP210-247 solution prepared 
in PBS (pH 7.4). This solution was let stand for 45 minutes at 37ºC. The sensing layer was then washed 
with PBS. Antibody binding was accomplished by casting standard solutions of Anti-CSP 210 and 
Anti-CSP 247 of increasing concentrations. Each standard was incubated for 30 minutes at 37ºC. 
Similarly, the positive serum samples were tested at several dilutions and the response of the sensing 
layer was evaluated to each degree of dilution. 
In detail, the first stage of modification includes the casting of carboxylated CNTs onto the carbon 
working electrode (Figure 1A). Only the necessary volume to cover the area of the working electrode 
was casted, thereby avoiding changes on counter or reference electrodes. This procedure was repeated 
three times. Each drop was allowed to dry before adding a new one.  
The resulting surface was then altered with the purpose of generating an amine layer. This was done 
in two stages. The first stage consisted on activating the –COOH functions on the CNTs with EDAC 
reaction, yielding the formation of a highly reactive O-acylisourea intermediate. This was followed by 
the immediate reaction with NHS, which produced an activated ester that was sufficiently unstable to 
undergo a nucleophilic substitution by any amine group (Figure 1B) (Jiang et al., 2004). The second 
stage achieves amination of the surface (Figure 1 C) by the addition of a di-amine compound to the 
activated carboxylic surface. The presence of this amine layer on the carbon-modified electrode was 
confirmed by a significant Rct increase in EIS, accounting the presence of non-conductive species over 
the surface. As observed before, SWV data recorded is more sensitive to concentration changes, while 
the changes in CV were less pronounced 
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The sensing layer was now ready to receive the proteins containing the antigenic epitopes to which the 
antibodies would bind. For this purpose, the protein solution was casted on the surface and incubated 
for 30 minutes (Figure 1D).  
The concentration of protein required at the surface and the time required for this binding to occur 
were also evaluated. It was important to ensure at this stage that the sensing surface was fully covered 
by protein in order to produce a sensitive and from chip-to-chip reproducible response against the 
antibodies in sera, and to reduce non-specific binding to the surface of other compounds present in 
sample matrix. To this end, the protein concentration was changed from 0.56 to 28 g/mL. The time 
given for protein binding was also varied within 30 and 60 minutes, as this may influence required 
protein concentration. Optimal conditions were found for a protein incubation along 45 minutes.  
 
2.6 Evaluation of the analytical performance 
The performance of each sensing layer was evaluated by incubating increasing concentrations of 
standard antibody solutions. This was done for single standard solutions of antibody (Anti-CSP 210 or 
Anti-CSP 247) and combined solutions (Anti-CSP 210 and Anti-CSP 247), all prepared in PBS buffer. 
The Anti-CSP 210 and Anti-CSP 247 concentrations ranged 9.59×10-11 to 1.70×10-5 µg/µL, prepared 
in PBS, lying within the linear range. All the assays were conducted in duplicates and the 
measurements were made by EIS. After incubation in each antibody concentration tested, the sensing 
layer was washed and evaluated in terms of electrical properties, by checking its response against a 
standard solution of 5.0×10-3 M K3[Fe(CN)6] and 5.0×10
-3 M K4[Fe(CN)6], prepared in PBS buffer, 
pH 7.4. 
The LOD was calculated as X+3σ, where X was the average value of EIS or SWV for blank signals 
(obtained in the absence of Anti-CSP 247, Anti-CSP 210 and Anti-CSP 210-247) and σ was the known 
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standard deviation of EIS or SWV for the blank signal (Harvey, 2000). All assays were conducted in 
duplicates.  
 
2.7 Analysis of samples 
The antibodies were assessed in different types of sera samples: One negative serum (acting as control 
and without Anti-CSP) and two sera containing Anti-CSP 210-247, but with different antibody levels. 
All sera were tested directly on the sensory element. The negative serum was also used to prepare 
standard solutions of antibodies Anti-CSP 210-247 (1:100 diluted in PBS buffer) in order to produce 
a calibration of the sensing layer in a serum background. The negative serum diluted in PBS buffer 
was also employed to carry out all necessary dilutions of the positive sera.  
 
3. Results and discussion 
 
3.1 CSP 210-247 chimeric protein production and purification 
The CSP protein of P. vivax occurs in two major forms produced by 2 different parasite strains. In 
order to be able to detect both forms, a chimeric CSP protein was produced expressed in HEK 293T 
cells and purified over a nickel column. The purity of the CSP protein was assessed by 12.5% SDS-
PAGE followed by visualization with Coomassie brilliant blue or Silver stain and was found to be 
>90%. Protein identity was confirmed by Western Blot using a His-tag specific antibody and CSP210 
and CSP247 monoclonal antibodies obtained from the Malaria Research and Reference Reagent 
Resource Centre (MRA).  
 
3.2 Assembly the sensing layer 
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A schematic representation of the steps used for the assembly of the sensing layer for capturing CSP 
210 and CSP 247-specific antibodies is shown in Figure 1. In a first step, the commercial SPEs were 
modified by CNTs to enhance the electrical properties of the layer which was followed by amidation 
and CSP was bound to the amine layer by electrostatic interactions. The maximum amount of CSP on 
the sensing area was achieved by casting 2.8 g/mL of protein for a period of 40 minutes.  
All chemical modifications made to generate the sensing layer were confirmed by following the 
changes in the typical CV, EIS and SWV records (Figure 2A, 2B and 2C) of a standard iron redox 
probe. EIS data is presented as Nyquist plots and fitted into the typical Randle’s equivalent circuit, 
where Rct is given by the diameter of the semicircle obtained in the plot.  
The obtained electrical signals showed that the electrical properties of the sensing layer were improved 
after casting carboxylated CNTs onto the carbon working electrode. The efficiency of this process was 
revealed most clearly by EIS assays; SWV data was also sensitive to this modification, while CV 
records were not as sensitivity. The next step consisted on the formation of an amine layer, to which 
the CSP protein was expected to bind with high affinity. This amine layer was linked to an Rct increase 
and lower current produced by SWV, as this new layer did not hold special conductivity features. As 
expected, the adsorption of the CSP protein to this amine layer was also linked to an additional Rct 
increase and current decrease in SWV assays. In general, CV data changes along the assembly 
procedure were not as sensitive as EIS or SWV. 
 
3.3 Antibody interaction with the sensing layer  
The sensing layer in Figure 1E was designed to be able to bind to Anti-CSP 210 and Anti-CSP 247 in 
serum by establishing a strong and selective binding. As antibody binding may be more effective at 
body temperature, the biosensor was first tested at 37 ºC. 
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To this end, a concentration of 0.17 ng/mL of monoclonal antibody standard solution was incubated 
first on the sensing layer, at 37ºC for 30 minutes. The antibody binding was confirmed by a peak 
potential shift in CV assays, linked to a wider potential range of peak separation (Figure 2D), a 
significant Rct increase of the sensing area in the Nyquist plots (Figure 2E), and a decrease of the peak 
current in SWV assays (Figure 2F). These signals were stable after consecutive washing periods and 
readings by the iron probe, thereby confirming the inert and stable interaction established between 
protein and antibody. 
The sensing layer was tested again with a higher antibody-concentration in order to know if the 
electrical changes observed were concentration dependent - a necessary feature to generate quantitative 
data from serum samples. A concentration of antibody of 1.7 ng/mL was selected for this purpose. As 
may be seen in Figures 2D, 2E and 2F, large electrical alterations were observed in EIS readings. The 
charge-transfer resistance of the sensing layer increased because an additional amount of protein 
(bound antibody) remained on the surface and hindered the access of the iron redox probe to the 
conductive support at the electrode surface. CV and SWV assays also detected additionally bound 
antibody, but the electrical changes were less pronounced than those in EIS. In addition, the oxidation 
peak of iron in the CV assays displayed a peak potential shift to lower values, which was not clearly 
consistent with the presence of the protein on the surface. Thus, SWV and EIS were found better 
electrochemical approaches for generating reliable quantitative data.  
 
3.4 Analytical performance of biosensor 
The analytical performance of the sensing layer assembled on commercial SPEs was evaluated by EIS 
and SWV measurements against increasing antibody concentrations, plotted as calibration curves. 
While EIS seems to produce more sensitive results, SWV proved to be the faster approach. The 
solutions used for this purpose contained monoclonal anti-CSP 247 or anti-CSP 210, or anti-CSP 247-
210, i.e. each antibody was tested individually as well as in combination in the same solution. The 
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concentrations of these antibodies ranged from 95.9 fg/mL to 17 ng/mL and all solutions (total 
concentration in the case of the combined antibodies, 1:1 ratio) were prepared in PBS buffer. 
In general, all EIS measurements (Figure 3) showed that increasing concentrations of Anti-CSP 247, 
Anti-CSP 210 and Anti-CSP 210-247 increased the charge-transfer resistance of the probe at the 
sensing layer. This was observed by the increasing diameter of the semicircles in the Nyquist plots and 
accounted additional amounts of protein bound to the surface. A good linear trend was obtained for 
Rct against logarithm of antibody concentration (Anti-CSP 247, Anti-CSP 210 or Anti-CSP 247-210), 
over a wide concentration range, from 95.9 fg/mL up to 17 ng/ml. Higher concentrations would be 
leading to the saturation of the sensing layer, while lower concentrations were probably not detected, 
as little differences were observed between the signals of the blank and the first standard of the 
calibration curve. The reproducibility of the sensing system was excellent, as confirmed by performing 
two independent calibrations with two independent separately assembled devices. For each specific 
antibody solution under study, the standard deviation of the slope of the calibration was reproducibly 
< 2.2%. Overall, similar calibration curve patterns were observed for all antibodies, both in single and 
combined solutions (table S2), indicating that they have high and similar affinities for the immobilized 
protein. Combining all calibrations (duplicates and different antibody solutions), the slope values were 
221±11.3 /decade, corresponding to about 5% changes in all these. This data clearly confirm the 
high precision of the system in terms of reproducibility, i.e. the standards may be changed as well as 
the device, but a 5% maximum deviation is observed. 
The calibration of the sensing layers by SWV (Figure S2) showed a similarly consistent behaviour as 
observed for EIS calibrations. The increased resistance occurring at the surface after antibody binding 
was revealed by a decrease of the current generated by the iron redox probe. Not all antibody solutions 
were tested in this study because there was not enough stock solution to prepare all necessary 
standards. As in EIS, no significant differences were observed when standard solutions of Anti-CSP 
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210 (Figure S2-A and S1-B) or Anti-CSP 210-247 (Figure S2-C and S2-D) were used. The replicate 
calibrations using new SPEs also confirmed the high reproducibility of the analytical response.  
Overall, both EIS and SWV showed strong sensitivity for both antibody solutions. The described 
sensing layer assembled on different batches of SPEs offered reproducible data and no significant 
variations were produced by the use of different calibrating solutions.  
 
3.5 CSP assay in sera samples 
To obtain information on the performance of the biosensor in a more realistic “real-life” situation, we 
evaluated its analytical output using four different types of mouse sera by plotting calibration curves 
as Rct (in EIS) and current intensity (I, in SWV) against logarithm of dilution. The first tested serum 
was a pre-immune negative control without Anti-CSP 210-24 antibodies. The second serum consisted 
of the negative serum spiked with different concentrations of both monoclonal antibodies (Anti-CSP 
210-247), which was used as a calibration plot for obtaining quantitative data from positive sera 
samples. The third serum tested was found weakly positive by ELISA while the fourth serum was 
highly positive for polyclonal anti-CSP 210-247 antibodies. A detailed description of these assays is 
presented next. 
 
3.5.1 Blank serum samples 
Blank serum samples were tested to identify the ability of the device to distinguish the antibodies 
related to Malaria from other components in serum. The sensing layer was first incubated in serum 
with a high degree of dilution and subsequently with decreasing dilution levels. Figure 4A and 4B 
depict signals obtained with this negative serum and no response in all measurements was observed, 
indicating that the biosensor did not pick up non-specific signals.  
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3.5.2 Spiked serum samples 
The analyse the effect of serum on antibody recognition, monoclonal antibodies were spiked into sera 
from naïve animals and electrical signals generated by the sensing layer were analysed. Figures 5C 
and 5D depict the responses induced by negative serum spiked with monoclonal antibodies. The linear 
trend had a slope of 152.86 /decade, which was similar to the one observed in buffer solutions. The 
response of the sensing layer followed the concentration of antibody from 95.9 fg/ml to 17 ng/ml, 
thereby allowing its application to real conditions. 
 
3.5.3 Positive sera samples 
First, assays were made with different serum samples that produced weak or strong responses in ELISA 
experiments. These samples were serially diluted in naive serum and incubated consecutively in the 
sensing layer (higher dilution to lower dilution). Each solution was allowed to equilibrate for 30 
minutes on the sensing layer. After that, the sensing layer was washed and followed by the iron probe 
reading, making use of both EIS and SWV techniques. 
Figures S3-A and S3-B show the sensitive response of the sensor to each of the diluted sera solutions 
(EIS and SWV, respectively), prepared from serum weakly positive in ELISA. The concentration of 
antibody in each of these dilutions was estimated using the calibration curve prepared with monoclonal 
antibodies in naïve serum (section 3.5.2). It was interesting to observe that all these dilution levels 
yielded similar concentrations for the original sample. The average value of antibody in serum was 
3.20.1 ng/L, corresponding to a standard deviation of 3.1%. So the sensing layer showed similar 
accuracy all over the wide linear range observed, also yielding precise data as confirmed by the small 
standard deviation.  
The strongly positive serum exhibiting higher levels of polyclonal anti-CSP 210-247 antibodies in 
ELISA was also serially diluted. Overall, the sensing layer showed a similar behaviour as observed 
16 
with the weakly positive serum (Figures S3-C and S3-D). As before, each dilution degree yielded 
similar levels of antibodies on the original samples. The average value was 20.90.5 ng/L, 
corresponding to a 2.4% standard deviation. The accuracy and the precision of the device are therefore 
confirmed for different levels of polyclonal antibodies.  
 
3.6 Direct sera readings 
Whether it was possible to measure antibody levels in undiluted sera was addressed next (Figure 5). 
Additional sera samples were used in this study. These samples contained different levels of antibodies 
as assessed by ELISA (1++, 2++, 3++ higher concentration; and 4+, 5+, 6+ medium concentration) in 
accordance with the schedule of vaccination, which used different doses of vaccines (with or without 
adjuvants) and time of blood sampling, reflecting natural variations seen after vaccination. As control, 
a group of mice was immunized with only PBS (negative control; samples 7, 8, 9 and 10).  
These results demonstrated that the biosensor was able to measure background free antibody levels in 
non-diluted sera, a pre-requisite for field-use. As may be seen in Figure 5A, all negative sera samples 
did not change the blank signal significantly and the sera samples with different levels (+ or ++) were 
grouped in terms of signal location. Using the calibration curve of the spiked blank serum samples, the 
concentrations deduced for these additional sera were: 308 ng/ml (1++); 37.4 ng/ml (2++); 2.89 ng/ml 
(3++); 119 pg/ml (4+); 22.3 pg/ml (5+) and 203 fg/ml (6+). 
 
3.8 Extension to a second malaria antigen 
In order to reveal whether the assembly of this sensing layer could be extended to other antigens, the 
same procedure was applied to a different protein of P. vivax. PvTrap was selected for this purpose 
since it is  also an important protein in the sporozoite of plasmodium, mainly responsible for induction 
of T cell responses (Bauza, et al., 2014). 
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As shown in Figure S4, a biosensor generated with PvTRAP was able to sensitively pick up anti-TRAP 
antibodies in a similar way as shown above for CSP. No concentrations were calculated this time, 
because there was no standard antibody available to perform a calibration curve. Still, the electrical 
changes generated by serial sample dilution confirmed the high sensitivity of the system for anti-
PvTrap (detecting levels of antibodies even after diluting the original serum by factor of 1.7×107), over 
a wide concentration range (linear range was observed between 300× to 1.7×107× dilutions). These 
findings confirm the high efficiency of this new way of producing a sensing layer against a circulating 
antibody and demonstrate that the here designed biosensor can be used in a general manner. 
Furthermore, a minimum of 10 months is indicated as lifetime for these devices. The ability of the 
sensors to respond after a long period of preparation was tested for PvTRAP-based sensors, stored in 
the refrigerator, under humid conditions. The results obtained pointed out that the sensor kept its ability 
to respond to the anti-PvTRAP in real serum, with similar sensitivity (Figure S5). It is important to 
highlight that the devices have been produced and stored at +4ºC in the context of the lifetime study 
(please see additional details in the supplementary section, S.6).  
From a durability perspective, and assuming this feature as the time along which the device may be 
useful after being in use, it is important to highlight that the proposed biosensor is a single use device. 
Once the antibody binds the sensing layer, it cannot be removed from the surface. So, the device is 
meant to be disposed-off after a single-use. Under real scenarios, this feature shall not limit the 
operation of the biosensor, because real samples are in contact with the electrode, and any attempt to 
reuse it rises health-safety concerns. 
 
4. Conclusions 
This work describes the development of a highly sensitive and inexpensive sensing layer for the rapid 
detection of the antibodies that circulate in the blood and signal a specific disease. The assembly of 
18 
the sensing element was made on a carbon commercial SPE (a generalist carbon surface, of low cost) 
and involved monolayer modifications of minimum complexity, providing very low detection limits 
in buffer and in sera, down to the range of 50 fg/ml, which corresponds to a concentration of about 10-
15M. As polyclonal antibodies usually have affinities of 10-9 to 10-10 M, this indicates that the here 
described sensor detects antibodies at concentrations well below the average affinity of the antibodies. 
A linear response was observed over a wide range of antibody concentrations, which is an 
advantageous feature, as initial levels of immune response are easily detected and undesired 
background effects may be avoided by establishing a higher degree of sample dilution. In addition, 
analytical readings may be established by EIS or SWV, depending on the technique that is available 
to perform on-site analysis.  
Comparing the current state-of-art techniques, this work describes significant advances. Firstly, there 
is no other work reporting the detection of antibodies specific for P. vivax. Secondly, the here described 
biosensor is far superior over previously reported systems for P. falciparum. Thirdly, the quality and 
reproducibility of the data is of the highest standards. 
Overall, the simple and sensitive strategy proposed herein is considered a promising approach for the 
routine field detection of pathogens and control of emerging diseases, hopefully even at the initial 
stages of disease outbreak. In terms of target(s), the sensing layer may be improved by extending the 
proposed design to a multiplex approach, where different antigenic proteins are casted over multiple 
SPEs. This will allow multiple analytical responses from a single serum drop, which could be directed 
towards a group of diseases or multiple antibodies of the same disease.   
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Legends for Figures 
 
Figure 1 Schematic illustration of electrochemical biosensor for detection of serum immune 
response. (A) Oxidation of carbon material; (B) Activated carboxylic acid ends; (C) 
Ethylenediamine, EDA, addition (D); incubation in CSP protein, 210-247; and (E) binding 
of the sensing layer to immune antibodies (Anti-210 and Anti-247). 
Figure 2 Electrochemical assays for control each step on graphene surface in 5.0×10-3 mol/L 
[Fe(CN)6 ]
3-  and 5.0×10-3 mol/L [Fe(CN)6]
4-, in PBS buffer with two concentrations of 
Anti-CSP 247 (0.17 and 1.7 ng/ml). CV (A, D), EIS (B, E) and SWV (C, F). 
Figure 3 EIS measurements (A, C and E) and that corresponding calibration curves (B, D and F) in 
5.0×10-3 M [Fe(CN)6]
3- and 5.0×10-3 M [Fe(CN)6]
4-, in PBS buffer pH 7.4, with different 
concentrations of Anti-CSP 247 (A and B), Anti-CSP 210 (C and D) and Anti-CSP 210-
247 (E and F). 
Figure 4 EIS (A and C) and SWV measurements (B and D) in 5.0×10-3 M [Fe(CN)6]
3- and 5.0×10-3 
M [Fe(CN)6]
4-, in PBS buffer pH 7.4, after incubation of blank serum with different 
dilution degrees (A and B) and blank serum spiked with Anti-CSP 210-247 ranging from 
95.9 fg/ml to 17 ng/ml (C and D). 
Figure 5 EIS measurements in 5.0×10-3 M [Fe(CN)6]
3- and 5.0×10-3 M [Fe(CN)6]
4-, in PBS buffer 
pH 7.4. (A) Negative sera samples (A) and positive sera samples (B) with higher 
concentration of antibodies (1++, 2++, and 3++) or medium concentration of antibodies 
(4+, 5+, and 6+). 
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Table 1: List of electrochemical methods used for Malaria detection.  
Organism Target Bioreceptor Platform LOD LR Ref. 
Plasmodium 
falciparum and 
Plasmodium vivax  
DNA fragments of 
malaria-infected 
blood 
Complementary DNA 
fragments of malaria 
biotinylated probe 
Silver/complementary 
hydribization  
  
(Ittarat et 
al., 2013) 
Plasmodium 
falciparum and 
Plasmodium vivax 
Plasmodium lactate 
dehydrogenase 
single-strand DNA 
aptamers for 
Plasmodium lactate 
dehydrogenase 
Gold Electrode 1 pM 1- 1000 pM  
(Lee et al., 
2012) 
Plasmodium 
falciparum 
Antibodies of 
Plasmodium 
falciparum histidine 
rich protein-2 
rabbit anti-PfHRP-2 
antibodies/ PfHRP-2 
complex 
SPE/Al2O3 sol–gel/ 
AuNPs  
Down to 
11 Dil. 
(1:102400)
. 
 
(Sharma et 
al., 2010) 
Plasmodium 
falciparum 
Plasmodium 
falciparum histidine 
rich protein-2 
rabbit anti-PfHRP-2 
antibodies 
Thioctic acid and 1-
dodecanethiol with 
antibody 
12 ng/ml 15–60 ng/ml 
(Sharma et 
al., 2011) 
Plasmodium 
falciparum 
Plasmodium falciparum 
Histidine-rich 
protein 2 
rabbit anti-PfHRP-2 
antibody 
Sample, followed by 
rabbit anti-mouse 
immunoglobulin G-
alkaline phosphatase 
8 ng/mL 
1:10 and 
1:50 
dilutions 
(Sharma et 
al., 2008) 
Plasmodium 
falciparum 
Plasmodium falciparum 
Histidine-rich 
protein 2 
Anti-PfHRP-2 antibodies 
Mercaptopropylphosp
honic acid 
functionalized copper 
doped zinc oxide 
nanofibers  
6 ag/mL 
10ag/ml-
10µg/ml  
(Brince 
Paul et al., 
2016) 
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Figure 3 
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Figure 5 
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